Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index
December 17, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the company has been added to the...
Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19
December 14, 2021 16:30 ET
|
Atea Pharmaceuticals, Inc.
Responding to the rapidly evolving SARS-CoV-2, emerging variants and changing treatment landscape, Atea is updating the development strategy for AT-527 In addition to monotherapy evaluation,...
Aptive Environmental Recognized On Inc.’s 2021 Best in Business List
December 07, 2021 13:46 ET
|
Aptive Environmental
PROVO, Utah, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Aptive Environmental, one of the fastest-growing pest control companies in North America, has been recognized on the Inc. 2021 Best in Business list as...
Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 22, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
November 16, 2021 16:30 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to...
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results
November 11, 2021 16:01 ET
|
Atea Pharmaceuticals, Inc.
Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment Infectious Virus Data...
Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021
November 04, 2021 07:53 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
For the 12th Time, Access Recognized on the Inc. 5000, With Three-Year Revenue Growth of 43 Percent
November 03, 2021 12:15 ET
|
Access
WOBURN, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Access, the world’s largest privately-held integrated information management services provider, today announced that it is being recognized for the...
Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting
October 19, 2021 07:00 ET
|
Atea Pharmaceuticals, Inc.
Topline Phase 2 MOONSONG trial results did not meet the primary endpoint in the overall population of patients with mild or moderate COVID-19, who were mostly low-risk with mild symptoms In high-risk...